Randomized Clinical Trial Finds Low-THC Full-Spectrum Cannabis Extract Significantly …
#80 Strong Clinical Relevance
High-quality evidence with meaningful patient or clinical significance.
In a randomized clinical trial published in Neurotherapeutics, researchers evaluated NTI164, a full-spectrum medicinal cannabis extract with less than 0.3% tetrahydrocannabinol (THC). The study found significant improvements in pain and sleep quality for patients with chronic neuropathic pain, suggesting potential therapeutic benefits for this patient population. Clinicians may consider NTI164 as a low-THC option for managing chronic neuropathic pain symptoms in appropriate cases.
🔬 In the realm of neurotherapy, a recent randomized clinical trial published in Neurotherapeutics has found significant improvements with NTI164, a low-THC full-spectrum cannabis extract. This study suggests potential benefits for patients dealing with treatment-resistant epilepsy. However, it’s crucial to acknowledge the complexity of individual patient responses and the need for further research to confirm these findings and identify any relevant confounders. In clinical practice, this trial underscores the importance of exploring various cannabis extract options as part of a comprehensive treatment plan for refractory epilepsy, always considering each patient’s unique circumstances and potential interactions with other medications.
💬 Join the Conversation
Have a question about how this applies to your situation? Ask Dr. Caplan →
Want to discuss this topic with other patients and caregivers? Join the forum discussion →
Have thoughts on this? Share it:
